Download PDF
Horm Metab Res 2017; 49(02): 122-128
DOI: 10.1055/s-0042-119788
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Growth Hormone Treatment Increases Plasma Irisin Concentration in Patients with Turner Syndrome

B. Wikiera   *
1   Department of Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Poland
,
K. Zawadzka   *
2   Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland
,
Ł. Łaczmański
2   Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland
,
N. Słoka
2   Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland
,
M. Bolanowski
2   Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland
,
A. Basiak
1   Department of Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Poland
,
A. Noczyńska
1   Department of Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Poland
,
J. Daroszewski
2   Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland
› Author Affiliations
Further Information

Publication History

received 03 August 2016

accepted 17 October 2016

Publication Date:
07 December 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Irisin (Ir) deficiency may be a contributing factor in metabolic disease. This study aimed to investigate the effect of supraphysiological doses of recombinant human growth hormone (rhGH) on Ir plasma concentration in relation to metabolic disorders, including obesity and other components of metabolic syndrome. We studied 36 girls with Turner syndrome (mean age 8.2 years) treated with rhGH (0.05 mg/kg/day). Anthropometric data and fasting blood levels [e. g., Ir, insulin, glucose, glycated hemoglobin (HbA1c), IGF-1, IGFBP-3, cholesterol, insulin resistance (HOMA-IR), and β-cell function (HOMA-β)] were analyzed prior to and following rhGH therapy [mean (SD) follow-up of 1.47 (0.89) years]. Insulin sensitivity (Matsuda index) was calculated before and after the glucose load. Following rhGH therapy, an increase in IGF-1 [mean (SD) of 119.40 (62.47) ng/ml to 439.08 (209.91) ng/ml, p=0.000], Ir [2.10 (1.03) μg/ml to 2.48 (0.78) μg/ml, p=0.036], HOMA-IR [median (IQR) of 0.64 (0.45–1.30) to 0.92 (0.67–2.36), p=0.0206], and HOMA-β values [45.00 (27.69–72.00) to 81.53 (51.43–132.00), p=0.0447] were observed. Multiple regression analysis yielded no associations between Ir and metabolic and hormonal parameters before rhGH treatment; however, on rhGH, the model (R2=0.56, adjusted R2=0.45) showed positive associations between Ir and IGF-1 standard deviation score and HbA1c, and negative associations between Ir and fasting blood glucose, HDL-cholesterol, and triglycerides. Despite manifestation of insulin resistance, rhGH application had a positive effect on Ir regulation, and restored physiological conditions of lipid and glucose metabolism.

Key words

irisin - growth hormone - insulin resistance - metabolic syndrome - HOMA-IR - beta-cell function

* The authors equally contributed to the paper.


 

  • References

  • 1 Lv J, Pan Y, Li X, Cheng D, Ju H, Tian J, Shi H, Zhang Y. Study on the distribution and elimination of the new hormone irisin in vivo: new discoveries regarding irisin. Horm Metab Res 2015; 47: 591-595
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Chronic Peroxisome Proliferator-activated Receptor ? (PPAR?) Activation of Epididymally Derived White Adipocyte Cultures Reveals a Population of Thermogenically Competent, UCP1-containing Adipocytes Molecularly Distinct from Classic Brown Adipocytes. J Biol Chem 2010; 285: 7153-7164
    CrossrefPubMedGoogle Scholar
  • 3 Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang A-H, Khandekar M, Nuutila P, Schaart G, Huang K, Tu H, van Marken Lichtenbelt WD, Hoeks J, Enerback S, Schrauwen P, Spiegelman BM. Beige Adipocytes are a Distinct Type of Thermogenic Fat Cell in Mouse and Human. Cell 2012; 150: 366-376
    CrossrefPubMedGoogle Scholar
  • 4 Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738
    CrossrefPubMedGoogle Scholar
  • 5 McMillan AC, White MD. Induction of thermogenesis in brown and beige adipose tissues: molecular markers, mild cold exposure and novel therapies. Curr Opin Endocrinol Diabetes Obes 2015; 22: 347-352
    CrossrefPubMedGoogle Scholar
  • 6 Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-839
    CrossrefPubMedGoogle Scholar
  • 7 Kraemer RR, Shockett P, Webb ND, Shah U, Castracane VD. A Transient Elevated Irisin Blood Concentration in Response to Prolonged, Moderate Aerobic Exercise in Young Men and Women. Horm Metab Res Horm Stoffwechselforschung Horm Metab 2014; 46: 150-154
    PubMedGoogle Scholar
  • 8 Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
    CrossrefPubMedGoogle Scholar
  • 9 Jóźków P, Medraś M. Growth hormone and IGF-1 as doping agents in competitive sport. Endokrynol Pol 2009; 60: 389-394
    PubMedGoogle Scholar
  • 10 Reinehr T, Lindberg A, Koltowska-Häggström M, Ranke M. Is growth hormone treatment in children associated with weight gain? Longitudinal analysis of KIGS data. Clin Endocrinol (Oxf) 2014; 81: 721-726
    CrossrefPubMedGoogle Scholar
  • 11 Meazza C, Elsedfy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res Horm Stoffwechselforschung Horm Métabolisme 2014; 46: 219-223
    PubMedGoogle Scholar
  • 12 Srinivasa S, Suresh C, Mottla J, Hamarneh SR, Irazoqui JE, Frontera W, Torriani M, Stanley T, Makimura H. FNDC5 relates to skeletal muscle IGF-I and mitochondrial function and gene expression in obese men with reduced growth hormone. Growth Horm IGF Res 2016; 26: 36-41
    CrossrefPubMedGoogle Scholar
  • 13 Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997; 16: 54-63
    CrossrefPubMedGoogle Scholar
  • 14 Bakalov VK, Cooley MM, Quon MJ, Luo ML, Yanovski JA, Nelson LM, Sullivan G, Bondy CA. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004; 89: 3516-3520
    CrossrefPubMedGoogle Scholar
  • 15 Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 2001; 86: 4166-4170
    CrossrefPubMedGoogle Scholar
  • 16 Lichiardopol C, Moţa M, Braicu D, Militaru C, Mixich F. Diabetes mellitus and Turner syndrome. Romanian J Intern Med Rev Roum Médecine Interne 2007; 45: 299-304
    PubMedGoogle Scholar
  • 17 Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, Amiel S, Press M, Tamborlane WV. Insulin resistance: an early metabolic defect of Turner’s syndrome. J Clin Endocrinol Metab 1991; 72: 832-836
    CrossrefPubMedGoogle Scholar
  • 18 Hazem A, Elamin MB, Bancos I, Malaga G, Prutsky G, Domecq JP, Elraiyah TA, Elnour NOA, Prevost Y, Almandoz JP, Zeballos-Palacios C, Velasquez ER, Erwin PJ, Natt N, Montori VM, Murad MH. Therapy in Endocrine Disease: Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol 2012; 166: 13-20
    CrossrefPubMedGoogle Scholar
  • 19 Darendeliler F, Aycan Z, Cetinkaya E, Vidilisan S, Bas F, Bideci A, Demirel F, Darcan S, Buyukgebiz A, Yildiz M, Berberoglu M, Arslanoglu I, Bundak R. Effects of growth hormone on growth, insulin resistance and related hormones (ghrelin, leptin and adiponectin) in Turner syndrome. Horm Res 2007; 68: 1-7
    PubMedGoogle Scholar
  • 20 Schweizer R, Martin DD, Schönau E, Ranke MB. Muscle function improves during growth hormone therapy in short children born small for gestational age: results of a peripheral quantitative computed tomography study on body composition. J Clin Endocrinol Metab 2008; 93: 2978-2983
    CrossrefPubMedGoogle Scholar
  • 21 Wikiera B, Bieniasz J, Barg E, Głab E, Noczyńska A. Lipoprotein a (Lp(a)) in patients with Turner’s syndrome. Pediatr Endocrinol Diabetes Metab 2010; 16: 29-32
    PubMedGoogle Scholar
  • 22 Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2008; 93: 2109-2114
    CrossrefPubMedGoogle Scholar
  • 23 Blüher S, Panagiotou G, Petroff D, Markert J, Wagner A, Klemm T, Filippaios A, Keller A, Mantzoros CS. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children. Obes Silver Spring Md 2014; 22: 1701-1708
    PubMedGoogle Scholar
  • 24 Palacios-González B, Vadillo-Ortega F, Polo-Oteyza E, Sánchez T, Ancira-Moreno M, Romero-Hidalgo S, Meráz N, Antuna-Puente B. Irisin levels before and after physical activity among school-age children with different BMI: a direct relation with leptin. Obes Silver Spring Md 2015; 23: 729-732
    PubMedGoogle Scholar
  • 25 Reinehr T, Elfers C, Lass N, Roth CL. Irisinand Its Relation to Insulin Resistance and Puberty in Obese Children: A Longitudinal Analysis. J Clin Endocrinol Metab 2015; 100: 2123-2130
    CrossrefPubMedGoogle Scholar
  • 26 Al-Daghri NM, Alkharfy KM, Rahman S, Amer OE, Vinodson B, Sabico S, Piya MK, Harte AL, McTernan PG, Alokail MS, Chrousos GP. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Invest 2014; 44: 119-124
    CrossrefPubMedGoogle Scholar
  • 27 Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016; DOI: 10.5603/EP.a2016.0030.
    PubMedGoogle Scholar
  • 28 Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function-newly discovered association. Peptides 2014; 60: 51-55
    CrossrefPubMedGoogle Scholar
  • 29 Elsheikh M, Dunger DB, Conway GS, Wass JaH. Turner’s Syndrome in Adulthood. Endocr Rev 2002; 23: 120-140
    PubMedGoogle Scholar
  • 30 Clement-Jones M, Schiller S, Rao E, Blaschke RJ, Zuniga A, Zeller R, Robson SC, Binder G, Glass I, Strachan T, Lindsay S, Rappold GA. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet 2000; 9: 695-702
    CrossrefPubMedGoogle Scholar
  • 31 Wikiera B, Mulak M, Koltowska-Haggstrom M, Noczynska A. The presence of eye defects in patients with Turner syndrome is irrespective of their karyotype. Clin Endocrinol (Oxf) 2015; 83: 842-848
    CrossrefPubMedGoogle Scholar
  • 32 Zhong Q, Layman LC. Genetic considerations in the patient with Turner syndrome-45,X with or without mosaicism. Fertil Steril 2012; 98: 775-779
    CrossrefPubMedGoogle Scholar
  • 33 Pena-Bello L, Pértega-Diaz S, Sangiao-Alvarellos S, Outeiriño-Blanco E, Eiras-Leal R, Varela-Rodriguez B, Juiz-Valiña P, Pérez-Fontán M, Cordido M, Cordido F. Circulating Levels of Irisin in Hypopituitary and Normal Subjects. PloS One 2016; 11: e0160364
    CrossrefPubMedGoogle Scholar
  • 34 Irzyniec TJ, Jeż W. The influence of hormonal replacement and growth hormone treatment on the lipids in Turner syndrome. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 2014; 30: 250-253
    PubMedGoogle Scholar
  • 35 Hee Park K, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907
    CrossrefPubMedGoogle Scholar
  • 36 Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 2013; 39: 125-130
    CrossrefPubMedGoogle Scholar
  • 37 Pukajło K, Łaczmański Ł, Kolackov K, Kuliczkowska-Płaksej J, Bolanowski M, Milewicz A, Daroszewski J. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 2015; 1-5
    PubMedGoogle Scholar
  • 38 Choi Y-K, Kim M-K, Bae KH, Seo H-A, Jeong J-Y, Lee W-K, Kim J-G, Lee I-K, Park K-G. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
    CrossrefPubMedGoogle Scholar
  • 39 Liu J-J, Wong MDS, Toy WC, Tan CSH, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 2013; 27: 365-369
    CrossrefPubMedGoogle Scholar
  • 40 Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778
    CrossrefPubMedGoogle Scholar
  • 41 Sanchis-Gomar F, Alis R, Pareja-Galeano H, Romagnoli M, Perez-Quilis C. Inconsistency in circulating irisin levels: what is really happening?. Horm Metab Res Horm 2014; 46: 591-596
    PubMedGoogle Scholar